Evaluation of the analytical and clinical characteristics of the Siemens IMMULITE®2000 TSI method for determining thyrotropin receptor antibodies
Method for determining thyrotropin receptor antibodies
Abstract
Background: Despite commercially improved, standardized routine methods used in medical laboratories, precision laboratory medicine lacks harmonization of results to make the laboratory result useful for its intended purpose. Furthermore, in order to obtain reliable laboratory results and precise diagnoses, it is important and recommended that each laboratory confirms the analytical and clinical characteristics of the method used. The aim of this study was to evaluate the analytical and clinical performance of the IMMULITE®2000 TSI bridge immunoassay for the determination of autoreactive thyroid stimulating hormone receptor antibodies (ТSH-R-Ab).
Methods: A total of 86 patients with clinically present Graves' orbitopathy and 23 healthy volunteers as a control group were included in the study. The total TSH-R-Ab concentration was determined using an ECLIA (Elecsys Anti-TSHR Immunoassay Roche Diagnostics, GmbH, Mannheim, Germany) on the Cobas e411 analyzer (Roche, Diagnostics, GmbH). The TSH-R-Ab concentration was measured using a CLIA method (IMMULITE TSI 2000, Siemens Healthcare Diagnostics, UK). The inaccuracy of the method was investigated using two levels of commercial control samples (low and high analyte concentration).
Results: The results obtained meet the general minimum requirements for the analytical performance of laboratory methods (CV <5%). The overall laboratory inaccuracy was acceptable according to FDA guidelines (CV<20%). The results showed a statistically significant correlation between the analyzed methods (r=0.9041, p ˂ 0.0001), but with a relative bias of 24.5%. The best ratio of sensitivity and specificity determined by the ROC analysis (93.3 % and 100 % respectively) was obtained for a cut-off value of 0.1215 IU/L, which is significantly lower compared to the cut-off value specified by the manufacturer (0.55 IU/L).
Conclusion: The IMMULITE 2000 TSI bridge immunoassay for TSH-R-Ab quantification confirmed an adequate level of precision, which is essential for routine use. However, further studies are required to evaluate its analytical specificity.
References
2. Smith BR, Sanders J, Furmaniak J. TSH receptor antibodies. Thyroid 2007; 17: 923–38.
3. Diana T, Kahaly GJ. Thyroid stimulating hormone receptor antibodies in thyroid eye disease-methodology and clinical applications. Ophthal Plast Reconstr Surg. 2018; 34: S13–9.
4. Ehlers M, Schott M, Allelein S. Graves' disease in clinical perspective. Front Biosci (Landmark Ed) 2019; 24: 35–47.
5. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010; 362: 726–38.
6. Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, Rrisk factors, and prevention of Graves’ orbitopathy. Front Endocrinol (Lausanne) 2020; 11: 615993.
7. Kahaly GJ, Diana T. TSH Receptor antibody functionality and nomenclature. Front Endocrinol (Lausanne) 2017; 8: 28.
8. Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 2010; 10: 116–22.
9. Gleicher N, Barad D, Weghofen A. Functional autoantibodies, a new paradigm in autoimmunity? Autoimmun Rev 2007; 7: 42–5.
10. Miguel N, Sanders J, Chirgadze DY, Furmanisak J, Smith RB. Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein–protein interactions. J Mol Endocrinol 2008; 42: 361–95.
11. Sanders J, Jeffreys J, Depraetere H, Richards T, Evans M, Kiddie A, et al. Thyroid-stimulating monoclonal antibodies. Thyroid 2002; 12: 1043–50.
12. Furmaniak J, Sanders J, Rees Smith B. Blocking type TSH receptor antibodies. Auto Immun Highlights 2012; 4: 11–26.
13. Morshed SA, Ando T, Latif R, Davies TF. Neutral antibodies to the TSH receptor are present in Graves’ disease and regulate selective signaling cascades. Endocrinology 2010; 151: 5537–49.
14. Roggenbuck JJ, Veiczi M, Conrad K, Schierack P, Wunderlich G, Kotzerke J, Roggenbuck D, Zöphel K. A novel third-generation TSH receptor antibody (TRAb) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding antibody. Immunologic Research. 2018; 66: 768-76.
15. Tozzoli R, D’Aurizio F, Villalta D, Giovanella L. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease. Clin Chem Lab Med. 2017; 55: 58–64.
16. Miao LY, Kim HJ, Whitlatch K, Jaiswal D, Navarro A, Egan R, Olivo PD. A rapid homogenous bioassay for detection of thyroid-stimulating antibodies based on a luminescent cyclic AMP biosensor. J Immunol Methods. 2022; 501: 113199.
17. Diana T, Wuster C, Kanitz M, Kahaly GJ. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest 2016; 39: 1159–65.
18. Ando T, Latif R, Davies TF. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance. Best Pract Res Clin Endocrinol Metab 2005; 19: 33–52.
19. Massart C, Gibassier J, d’Herbomez M. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves’ disease: comparison with the second generation human TRAb assay. Clin Chim Acta. 2009; 407: 62–6.
20. Schott M, Hermsen D, Broecker-Preuss M, et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves’ disease (GD): an international multicentre trial. Clin Endocrinol (Oxf). 2009; 71: 566–73.
21. Bell L, Hunter AL, Kyriacou A, Mukherjee A, Syed AA. Clinical diagnosis of Graves’ or non-Graves’ hyperthyroidism compared to TSH receptor antibody test. Endocrine Connections. 2018; 7: 504–10.
22. Diana T, Wüster C, Olivo PD, Unterrainer A, König J, Kanitz M, et al. Performance and specificity of 6 immunoassays for tsh receptor antibodies: A multicenter study. Eur Thyroid J 2017; 6: 243–9.
23. National Guide to Good Clinical Practice. Dysfunction of the thyroid gland. Clinical Guide 3/11. The Republic's expert commission for the development and implementation of good clinical practice guidelines. Ministry of Health of the Republic of Serbia in 2011.
24. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J 2018; 7: 167–86.
25. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C. The 2021 European group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 2021; 185: G43–67.
26. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997; 47(1): 9–14. doi: 10.1046/j.1365-2265.1997.2331047.x. Erratum in: Clin Endocrinol (Oxf) 1997; 47: 632.
27. CLSI. User Verification of Precision Implementation Guide. 1st ed. CLSI implementation guide EP15-Ed3-IG1. Clinical and Laboratory Standards Institute; 2021.
28. CLSI. User Verification of Bias (Trueness) Implementation Guide. 1st ed. CLSI implementation guide EP15-Ed3-IG2. Clinical and Laboratory Standards Institute; 2021.
29. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures
30. Chesher D. Evaluating assay precision. Clin Biochem Rev. 2008; 29: S23–6.
31. Ćelap I, Vukasović I, Juričić G, Šimundić AM. Minimum requirements for the estimation of measurement uncertainty: Recommendations of the joint Working group for uncertainty of measurement of the CSMBLM and CCMB. Biochem Med. 2017; 27: 030502.
32. https://biologicalvariation.eu/
33. Theodorsson E. Validation and verification of measurement methods in clinical chemistry. Bioanalysis 2012; 4: 305–20
34. Frank CU, Braeth S, Dietrich JW, Wanjura D, Loos U. Bridge Technology with TSH receptor chimera for sensitive direct detection of TSH receptor antibodies causing Graves' disease: analytical and clinical evaluation. Horm Metab Res 2015; 47: 880–8.
35. Allelein S, Diana T, Ehlers M, Kanitz M, Hermsen D, Schott M, et al. Comparison of a bridge immunoassay with two bioassays for thyrotropin receptor antibody detection and differentiation. Horm Metab Res 2019; 51: 341–46.
36. Sarić-Matutinović M, Diana T, Nedeljković-Beleslin B, Ćirić J, Žarković M, Perović-Blagojević I, Kahaly GJ, Ignjatović S. Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy. J Med Biochem. 2022; 41: 211–20.
37. McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid 2013; 23: 14–24.
38. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012; 12: 107–13.
39. Kim JJ, Jeong SH, Kim B, Kim D, Jeong SH. Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay. Scandinavian Journal of Clinical and Laboratory Investigation. 2019; 6: 443–8.
Copyright (c) 2025 Neda Milinković, Marija Sarić, Ana Ružanović, Miloš Žarković, Jasmina Ćirić, Iva Perović Blagojević, Ana Marija Mastilović, Svetlana Ignjatović, Biljana Nedeljković Beleslin
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.